- Home
- SOWG vs INDP Comparison
SOWG vs INDP Comparison
Compare SOWG & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | INDP |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.5M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOWG | INDP |
|---|---|---|
| Price | $0.44 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 19.2K |
| Earning Date | 03-20-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.20 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,992,511.00 | N/A |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.07 | N/A |
| 52 Week Low | $0.23 | $0.27 |
| 52 Week High | $2.12 | $13.24 |
Technical Indicators
Market Signals| Indicator | SOWG | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 39.06 |
| Support Level | $0.38 | $0.27 |
| Resistance Level | $0.47 | $2.18 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 32.28 | 5.06 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.